Page 2 - Spring Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global Neutropenia Treatment Market To Be Driven By Increasing Awareness Of Neutropenia And Side-Effects Of Chemotherapy During The Forecast Period Of 2022

BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.